var data={"title":"Entecavir: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Entecavir: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6107?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=entecavir-patient-drug-information\" class=\"drug drug_patient\">see &quot;Entecavir: Patient drug information&quot;</a> and <a href=\"topic.htm?path=entecavir-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Entecavir: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708732\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Severe acute exacerbations of hepatitis B:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued anti&ndash;hepatitis B therapy, including entecavir. Closely monitor hepatic function with clinical and laboratory follow-up for at least several months in patients who discontinue anti&ndash;hepatitis B therapy. If appropriate, initiation of antihepatitis B therapy may be warranted.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">HIV and chronic hepatitis B virus coinfection:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Limited clinical experience suggests there is a potential for the development of resistance to HIV nucleoside reverse transcriptase inhibitors if entecavir is used to treat chronic hepatitis B virus (HBV) infection in patients with HIV infection not being treated. Therapy with entecavir is not recommended for HIV/HBV coinfected patients who are not also receiving antiretroviral therapy.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Lactic acidosis and hepatomegaly:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogue inhibitors alone or in combination with antiretrovirals.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165232\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Baraclude</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4297830\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Entecavir;</li>\n      <li>Auro-Entecavir;</li>\n      <li>Baraclude;</li>\n      <li>PMS-Entecavir</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165244\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antihepadnaviral, Reverse Transcriptase Inhibitor, Nucleoside (Anti-HBV)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165233\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hepatitis B virus (HBV) infection, treatment:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nucleoside treatment naive: 0.5 mg once daily</p>\n    <p style=\"text-indent:-4em;margin-left:6em;\">Lamivudine-refractory or -resistant viremia (or known lamivudine- or telbivudine-resistant mutations): 1 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Decompensated liver disease: 1 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Treatment duration (AASLD practice guidelines):</i> Treatment duration for nucleos(t)ide analog-based therapy (eg, entecavir) is variable and influenced by HBeAg status, duration of HBV suppression, and presence of cirrhosis/decompensation (AASLD [Terrault 2016]):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Patients <i>without</i> cirrhosis:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hepatitis B e antigen (HBeAg) positive immune-active chronic hepatitis: Treat until HBeAg seroconversion; after seroconversion, prolonged duration of therapy is often required in patients treated with nucleos(t)ide anaglogues,. Optimal duration is unknown; however, consolidation therapy is generally a minimum of 12 months of persistently normal ALT and undetectable serum HBV DNA levels after HBeAg seroconversion</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">HBeAg-negative immune-active chronic hepatitis: Indefinite antiviral therapy is suggested unless there is competing rationale for discontinuation (risk/benefit decision); treatment discontinuation may be considered in patients with loss of HBsAg; however, there is insufficient evidence to guide decisions in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Patients <i>with </i>cirrhosis:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">HBeAg-positive immune-active chronic hepatitis: In patients who seroconvert on therapy, continue antiviral therapy indefinitely due to concerns with decompensation and death, unless there is a strong competing rationale for discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">HBeAg-negative immune-active chronic hepatitis: Treatment discontinuation is not recommended due to potential for decompensation and death (limited data).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Viral breakthrough (AASLD practice guidelines):</i> Patients with confirmed viral breakthrough (HBV DNA &ge; 100 IU/mL with previously undetectable levels [&lt;10 IU/mL] or &gt;1 log increase in HBV DNA) should either be switched to an alternative antiviral monotherapy agent with a high genetic barrier to resistance <b>or</b> receive a second antiviral agent with a complementary resistance profile; consult current clinical practice guidelines for recommended agents (AASLD [Terrault 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HBV reinfection prophylaxis, post liver transplant (with or without HBIG) (off-label use):</b> Oral: 0.5 mg once daily (Fung, 2011) or 1 mg once daily (Perrillo 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HIV/HBV coinfection (off-label use): </b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nucleoside treatment naive: 0.5 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lamivudine refractory or resistant: 1 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Only recommended in patients who cannot take tenofovir; must be used in addition to a fully suppressive antiretroviral therapy regimen (DHHS, 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165239\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=entecavir-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Entecavir: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;\">\n      <b>Hepatitis B virus (HBV) infection, treatment (nucleoside treatment na&iuml;ve or lamivudine-refractory or -resistant viremia [or known lamivudine- or telbivudine-resistance mutations]):</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children &ge;2 years and Adolescents: Oral: <b>Note:</b> Oral solution should be used for patients weighing &le;30 kg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment-naive:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">10 to 11 kg: 0.15 mg once daily (oral solution)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;11 to 14 kg: 0.2 mg once daily (oral solution)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;14 to 17 kg: 0.25 mg once daily (oral solution)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;17 to 20 kg: 0.3 mg once daily (oral solution)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;20 to 23 kg: 0.35 mg once daily (oral solution)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;23 to 26 kg: 0.4 mg once daily (oral solution)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;26 to 30 kg: 0.45 mg once daily (oral solution)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;30 kg: 0.5 mg once daily (oral solution or tablet)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lamivudine-experienced:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">10 to 11 kg: 0.3 mg once daily (oral solution)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;11 to 14 kg: 0.4 mg once daily (oral solution)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;14 to 17 kg: 0.5 mg once daily (oral solution)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;17 to 20 kg: 0.6 mg once daily (oral solution)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;20 to 23 kg: 0.7 mg once daily (oral solution)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;23 to 26 kg: 0.8 mg once daily (oral solution)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;26 to 30 kg: 0.9 mg once daily (oral solution)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;30 kg: 1 mg once daily (oral solution or tablet)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165234\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165235\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults: Daily-dosage regimen preferred:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;50 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 30-49 mL/minute: Administer 50% of usual dose daily or administer the normal dose every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 10-29 mL/minute: Administer 30% of usual dose daily or administer the normal dose every 72 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;10 mL/minute (including hemodialysis and CAPD): Administer 10% of usual dose daily or administer the normal dose every 7 days; administer after hemodialysis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children &gt;2 years and Adolescents: Insufficient data to recommend a specific dose adjustment in pediatric patients with renal impairment; consider a reduction in the dose or an increase in the dosing interval similar to adjustments for adults.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4472037\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children &gt;2 years and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165216\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Baraclude: 0.05 mg/mL (210 mL) [contains methylparaben, propylparaben; orange flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Baraclude: 0.5 mg, 1 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.5 mg, 1 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165206\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165218\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer on an empty stomach (2 hours before or after a meal). Do not dilute or mix oral solution with water or other beverages; use calibrated oral dosing syringe. Oral solution and tablet are bioequivalent on a mg-to-mg basis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132423\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165217\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Chronic hepatitis B: </b>Treatment of chronic hepatitis B virus (HBV) infection in adults and pediatric patients 2 years and older with evidence of active viral replication and either evidence of persistent transaminase elevations or histologically-active disease. <b>Note: </b>In adults, indication is based on data in patients with compensated and decompensated liver disease; in children, indication is based on data in patients with compensated liver disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25473578\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Hepatitis B virus (HBV) reinfection prophylaxis, post liver transplant; HIV/HBV coinfection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165210\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Adverse reactions are generally similar in adult and pediatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Peripheral edema (16% with decompensated liver disease)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Ascites (15% with decompensated liver disease), increased serum ALT (&gt;5 x ULN: 11% to 12%; post-treatment flare [lamivudine refractory]: &gt;10 x ULN and &gt;2 x baseline: 12%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renal: Increased serum creatinine (11% with decompensated liver disease; 1% to 2% with compensated liver disease) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever (14% with decompensated liver disease)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Headache (2% to 4%), fatigue (1% to 3%), dizziness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Skin rash  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Glycosuria (4%), hyperglycemia (2% to 3%), decreased serum bicarbonate (2% with decompensated liver disease)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Increased serum lipase  (7%), increased serum amylase (2% to 3%), abdominal pain (children and adolescents &gt;1%), diarrhea (children and adolescents &gt;1%; adults &le;1%), unpleasant taste (children and adolescents &gt;1%), vomiting (children and adolescents &gt;1%; adults &lt;1%), dyspepsia (&le;1%), nausea</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Hematuria (9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Hepatic carcinoma (6% with decompensated liver disease)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Hepatic encephalopathy (10% with decompensated liver disease), increased serum bilirubin (2% to 3%), increased serum ALT (&gt;10 x ULN and &gt;2 x baseline: 2%; post-treatment flare [nucleoside-naive]: &gt;10 x ULN and &gt;2 x baseline: 2% to 8%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Upper respiratory tract infection (10% with decompensated liver disease)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Alopecia, anaphylactoid reaction, drowsiness, hepatomegaly, hypersensitivity, hypoalbuminemia, increased serum transaminases, insomnia, lactic acidosis, leukopenia, macular edema (Muqit, 2011), neutropenia, pancreatitis, renal failure, thrombocytopenia, upper abdominal pain  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165220\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer's US labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Canadian labeling: Hypersensitivity to entecavir or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165208\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lactic acidosis/hepatomegaly: <b>[US Boxed Warning]: Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have been reported with nucleoside analogue inhibitors;</b> use with caution in patients with risk factors for liver disease (risk may be increased with female gender, decompensated liver disease, obesity, or prolonged nucleoside inhibitor exposure) and suspend treatment in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or hepatotoxicity (transaminase elevation may/may not accompany hepatomegaly and steatosis).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chronic hepatitis B: <b>[US Boxed Warning]: Severe, acute exacerbation of hepatitis B may occur upon discontinuation of antihepatitis B therapy, including entecavir. Monitor liver function for at least several months after stopping treatment; reinitiation of antihepatitis B therapy may be required.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; HIV: <b>[US Boxed Warning]: May cause the development of HIV resistance in chronic hepatitis B patients with unrecognized or untreated HIV infection.</b> Determine HIV status prior to initiating treatment with entecavir. <b>Not recommended for HIV/HBV coinfected patients unless also receiving antiretroviral therapy. </b>The manufacturer's labeling states that entecavir does not exhibit any clinically-relevant activity against human immunodeficiency virus (HIV type 1). However, a small number of case reports have indicated declines in virus levels during entecavir therapy. HIV resistance to a common HIV drug has been reported in an HIV/HBV-infected patient receiving entecavir as monotherapy for HBV.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Dose adjustment not required. Limited data supporting treatment of chronic hepatitis B in patients with decompensated liver disease; observe for increased adverse reactions, including hepatorenal dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment or patients receiving concomitant therapy which may reduce renal function; dose adjustment recommended for CrCl &lt;50 mL/minute.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Children: There are limited data available on the use of entecavir in lamivudine-experienced pediatric patients; use in these patients only if the potential benefit justifies the potential risk to the child.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson, 2002; Lucente 2000; Shelley, 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade, 1986; CDC, 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Resistance: Cross-resistance may develop in patients failing previous therapy with lamivudine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299265\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3053493\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8816&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Antiretroviral Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165229\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Food delays absorption and reduces AUC by 18% to 20%. Management: Administer on an empty stomach 2 hours before or after a meal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165213\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165221\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Teratogenic effects have been observed in animal studies. Information related to use in pregnancy is limited; use only if other options are inappropriate (DHHS [OI], 2013). Pregnant women taking entecavir should enroll in the pregnancy registry by calling 1-800-258-4263.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20617099\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if entecavir is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165222\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Take on an empty stomach (2 hours before or after a meal).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165214\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Manufacturer&rsquo;s labeling: HIV status (prior to initiation of therapy); periodic monitoring of hepatic function is recommended during treatment and for at least several months after treatment in patients who discontinue anti-hepatitis B therapy. Monitor patients for signs and symptoms of lactic acidosis and hepatotoxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alternate recommendations: Chronic Hepatitis B: HBV DNA and ALT (HBV DNA usually done every 3 months until undetectable and then every 3 to 6 months thereafter); HBeAg; anti-HBe (in patients who are HBeAg-positive to monitor for seroconversion); HBsAg; consider monitoring lactic acid levels (if clinical concern); following discontinuation, monitor for recurrent viremia, ALT flares, seroreversion, and clinical decompensation every 3 months for at least 1 year (AASLD [Terrault 2016]). As antivirals do not eliminate the risk of hepatocellular carcinoma, continued monitoring for this complication is recommended in at-risk patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165207\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Entecavir is intracellularly phosphorylated to guanosine triphosphate which competes with natural substrates to effectively inhibit hepatitis B viral polymerase; enzyme inhibition blocks reverse transcriptase activity thereby reducing viral DNA synthesis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165219\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">\n      <b>Note:</b> The pharmacokinetics of pediatric patients &ge;2 years are similar to adult values. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Delayed with food; C<sub>max</sub> decreased 44% to 46%, AUC decreased 18% to 20%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Extensive (V<sub>d</sub> in excess of body water) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~13% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Minor hepatic glucuronide/sulfate conjugation </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Tablet and oral solution are bioequivalent. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Terminal: ~5-6 days; accumulation: ~24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: 0.5-1.5 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (60% to 73% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3422226\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Baraclude Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05 mg/mL (210 mL): $1,152.86</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Baraclude Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (30): $1,646.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (30): $1,646.98</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Entecavir Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (30): $1,333.05</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (30): $1,333.05</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4301433\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Agicarvir (VN);</li>\n      <li>Bacavir (KR);</li>\n      <li>Baraclude (AE, AR, AT, AU, BB, BE, BG, BH, BR, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EE, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, ID, IE, IL, IS, IT, JO, JP, KR, KW, LB, LT, LU, LV, MT, MY, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, SV, TH, TR, TW, UY, VN);</li>\n      <li>Baracross (PH);</li>\n      <li>Baraenter (KR);</li>\n      <li>Baraliver (KR);</li>\n      <li>Baratis Film (KR);</li>\n      <li>Barcavir (BD);</li>\n      <li>Encavir (KR);</li>\n      <li>Encavor (HK);</li>\n      <li>Enped (KR);</li>\n      <li>Entavir (BD);</li>\n      <li>Enteca (KR);</li>\n      <li>Entecabell (KR);</li>\n      <li>Enteclud (VN);</li>\n      <li>Entegard (PH);</li>\n      <li>Enteone (KR);</li>\n      <li>Entikav (HK);</li>\n      <li>Nulesavir (VN);</li>\n      <li>Tecavir (BD);</li>\n      <li>Teviral (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/entecavir-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Auro-Entecavir (entecavir) [product monograph]. Woodbridge, Ontario, Canada: Auro Pharma Inc, November 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baraclude (entecavir) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; August 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/entecavir-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Department of Health and Human Services. Updated May 1, 2014. Available at <a href=\"http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf\" target=\"_blank\">http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. November 2013. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. October 2014. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed November 12, 2014</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21762659\"></a>Fung J, Cheung C, Chan SC, et al, &quot;Entecavir Monotherapy is Effective in Suppressing Hepatitis B Virus After Liver Transplantation,&quot; <i>Gastroenterology</i>, 2011, 141(4):1212-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/entecavir-drug-information/abstract-text/21762659/pubmed\" target=\"_blank\" id=\"21762659\">21762659</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/entecavir-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Muqit MK, Stanga PE, Vilar FJ, et al. Presumed entecavir-induced ocular toxicity. <i>Eye (Lond)</i>. 2011;25(12):1665-1668.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/entecavir-drug-information/abstract-text/22020173/pubmed\" target=\"_blank\" id=\"22020173\">22020173</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"Perrillo.2012\"></a>Perrillo R, Ferret MB, Durand F, et al, &quot;Safety and Efficacy of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B,&quot; 47th Annual Meeting of the European Association for the Study of the Liver, Barcelona, Spain; 2012, Poster 535.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/entecavir-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH; American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. <i>Hepatology</i>. 2016;63(1):261-283. doi: 10.1002/hep.28156.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/entecavir-drug-information/abstract-text/26566064/pubmed\" target=\"_blank\" id=\"26566064\">26566064</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    NIOSH recommends double gloving, a protective gown, and (if liquid that could splash) eye/face protection for administration of a topical product; if there is potential for inhalation, respiratory protection is recommended (NIOSH 2016).</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8816 Version 166.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708732\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F165232\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F4297830\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F165244\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F165233\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F165239\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F165234\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F165235\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F4472037\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F165216\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F165206\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F165218\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132423\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F165217\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25473578\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F165210\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F165220\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F165208\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299265\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F3053493\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F165229\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F165213\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F165221\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20617099\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F165222\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F165214\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F165207\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F165219\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F3422226\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F4301433\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8816|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=entecavir-patient-drug-information\" class=\"drug drug_patient\">Entecavir: Patient drug information</a></li><li><a href=\"topic.htm?path=entecavir-pediatric-drug-information\" class=\"drug drug_pediatric\">Entecavir: Pediatric drug information</a></li></ul></div></div>","javascript":null}